DOCSLIB.ORG

CURRICULUM VITAE Name: John E. Koundourellis Address: School Of

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
CURRICULUM VITAE Name: John E. Koundourellis Address: School Of CURRICULUM VITAE Name: John E. Koundourellis Address: School of Pharmacy, Department of Pharmaceutical Technology, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece. Tel: +302310997643, Fax: +302310997652 e-mail: [email protected] Job Title: Associate Professor Marital status: Married / two children Education 1973 Pharmacy degree (School of Pharmacy, Aristotelian University of Thessaloniki, Greece) 1978 M. Phil. Degree (School of Pharmacy, University of Bath, Avon, England) 1981 Ph.D (School of Pharmacy, University of Bath, Avon, England) Research Interests: · Development various chromatographic systems for the quantification of drugs and their metabolites in pharmaceutical preparations and in biological fluids · Quantification of drugs by employing zero order and derivative spectra · Characterization of drugs and their polymorphic forms using X-ray diffraction data Infrared and Raman Spectrophotometry Publications: Theses 1. J. E. Kountourellis, Spectrometric and Spectrophotometric Analysis of 2- lmidazolines, M. Phil Thesis, Bath University, September 1978 2. J. E. Kountourellis, Carbon -13 NMR Quantitative and Qualitative Analysis. Ph. D. Thesis, Bath University, September 1981 Papers in Scientific Journals 1. × - Ray Powder Diffraction Data for Nine Medicinal 2 - Imidazolines J.T.R. Owen, J.E. Kountourellis, F.A. Underwood, Journal of the Association of Official Analytical Chemists 64, No 5,1164 - 1173(1981). 2. Studies of carbon -13 n.m.r. spectroscopy in pharmaceutical analysis: the composition of commercial samples of gentamicin sulphate. J.E. Kountourellis, R.T. Parfitt, A.F. Casy Journal of Pharmacy and Pharmacology 35: 279-283 (1983). 3. Mass Spectra and Fragmentation Pathways of two Medicinal Aryl -I midazo-lines under Electron Impact. J.E. Kountourellis, Pharmakeftiko Deltio, Vol X, 47- 54, (1984) 4. Ultraviolet Spectral Structure Studies of Five Amidines of Pharmaceutica Énterest, I.E. Kountourellis, Pharmakeftiko Deltio, Scientific Edition, XI, 43-53 (1985). 5. X-ray powder diffraction data for propantheline bromide J.E. Kountourellis and A. Raptouli. Acta Pharmaceutica Suecica, Vol.22,1,59-61 (1985) 6. Determination of Thermodynamic lonization Constants for Eight Medici- nal Benzylimidazolines. J.E. Kountourellis, N. Papadopoulos and A. Raptouli. Talanta,Vol.31,9,730 (1984). 7. Determination of Vitamin A and Å in Pharmaceutical Preparations by HPLC Method. J.E. Kountourellis, A. Raptouli, N.A. Botsoglou and M. Georgarakis. Die Pharmazie 40,H.3, 193-194 (1985). 8. Quantitative applications of 13C NMR Spectroscopy to pharmaceutical analysis J.E. Kountourellis Pharmacy International Vol. 7, 2, 4145 (1986) 9. Simultaneous determination of bromochlorosalicylanillideand bamipine in pharmaceutical formulations by High Performance Liquid Chromatography. J.E. Kountourellis, A. Raptouli and P.P. Georgakopoulos Journal of Chromatography,362,3439-42(1986) 10. Simultaneous Determination of Aminophylline and Promethazine in Suppositories by High-Performance Liquid Chromatography. John E. Kountourellis, Antonia Raptouli and Manoiis Georgarakis, Die Pharmazie, Vol. 41, 4-8 (1986) 11. × – Ray Diffraction data for six analgesics. J.E. Kountourellis, F.A. Underwood, and P.P. Georgakopoulos and A. Raptouli Talanta, Vol. 33 No 7 631-632 (1986) 12. Simultaneous Determination of 2-imidazolines and Other Pharmaceutical Substances in Commercial Preparations by High- Per-formance Liquid-Chromatography. J.E. Kountourellis and A. Raptouli Analytical Letters, 21 (8), 1361-1370 (1988) 13. An Analytical Study of Eight Medicinal 2-lmidazolines by Ç and 13C Nuclear Magnetic Resonance Spectroscopy. J.E. Kountourellis Pharmazie 43, Ç 1, 26-29 (1988) 14. Effect of Particle Size, Content in Lubricant, Mixing Time and Storage Relative Humidity on Drug Release from Hard Gelatin Capsules. M. Georgarakis, P. Hatzipantou and J.E. Kountourellis. Drug Development and Industrial Pharmacy 14, 915-923 (1988) 15. A Simultaneous Assay by High Performance Liquid Chromato-graphy of Bamipine Hydrochloride and Terbutaline Sulphate in Dosage Forms. J.E. Kountourellis and Catherine Markopoulou. Journal of Liquid Chromatography, 12(16), 3279-3286 (1989) 16. Rapid Isocraric High-Performance Chromatographic Determination of Some Hypnotics/Sedatives in the Presence of Phenytoin in Commercial Formulations. J.E. Kountourellis and C. Markopoulou Indian Drugs, Vol. 27, N° 1, p.p. 66-70 (1989) 17. .Separation and simultaneous determination of bamipine and salbutamol in dosage forms by high-performance liquid chromatography. J.E. Kountourellis, C. Markopoulou and P. Georgakopoulos Journal of Chromatography, 502, 189-192 (1990) 18. RNA Methylation as a Key-Regulatory Process in Growth and Differentiation of Murine Erythroleukemia (MEL) Cells : Inhibition by Í6 - Methyl-adenosine (N6meAdo). J.S. Vizirianakis, C.K. Markopoulou, J.E. Kountourellis, L.C. Papadopoulou and A.S. Tsiftsoglou. 81stAnnual Meeting of the American Association for Cancer Research, Washington DC. Proceedings, Vol. 31, 206( 1990). 19. A HPLC Method for the Separation and Simultaneous Determination of Antihistamines Sympathomimetic Ámines and Dextrome-thorphan in Bulk Drug Material and Dosage Forms. J.E. Kountourellis, C.K. Markopoulou and P.P. Georgakopoulos Analytical Letters, 23 (5), 883-891 (1990). 20. X-Ray Powder Diffraction Data for Nine Analgesics J.E. Kountourellis, C.K. Markopoulou, F.A. Underwood and B. Chapman Talanta 33,2,233-235(1990). 21. A Simultaneous Analysis by High Performance Liquid Chromatography of Bamipine Combined with Tricyclic Antidepressants and/or Antiphychotics in Dosage Forms John E. Kountourellis and Catherine K,. Markopoulou Journal of Liquid Chromatography, 14/15, 2969-2977 (1991) 22. X-Ray Characterization of 12 Diuretics J.E. Kountourellis, C.K. Markopoulou and F.A. Underwood, B.Chapman Journal of Chemical of Engineering Data, 37(2), 187-191, American Chemical Society (1992). 23. X.Ray Powder Diffraction Data for Spironolactone J.E.Kountourellis and C.K. Markopoulou Chemical and Environmental Research 11, 103-105(1992 24. Determination of Vitamin A and E in Therapeutic and Cosmetic Creams Using Solid Phase Extraction (SPE) and High Performance Liquid Chromatograph (HPLC) John E. Kountourellis, Catherine Markopoulou and Byron K. Nathaniel Chem. Environ. Research 1(2) 1992, 83-87 25. Quantitative High Performance Liquid Chromatographic Determination of Bamipine Combined with Tricyclic Antidepressants and/or Antipsychotics in Pharmaceutical Formulations John E. Kountourellis, Catherine K. Markopoulou and John A. Stratis Analytical Letters, 26(10), 2171-2182 (1993) 26. Reversed-Phase High Performance Liquid Chromatographic Determination of Cyproheptadine from Urine by Solid-Phase Extraction John E. Kountourellis*, Kenneth O. Ebete Journal of Chromatography B, 664 (1995) 468-471 27. Separation and Determination of Some Corticosteroids Combined with Bamipine in Pharmaceutical Formulations by High Performance Liquid Chromatography J.E. Kountourellis*, C.K. Markopoulou, K.O. Ebete, and J.A. Stratis Journal of Liquid Chromatography, 18(17), 3507-3517 (1995) 28. Determination of Pimethixene in Plasma and Urine by High Performance Liquid Chromatography J.E. Kountourellis* and K.O. Ebete Analytical Letters, 29(5), 775-784 (1996) 29. Determination of Diphenylpyraline in Plasma and Urine by High- Performance Liquid Chromatography Kenneth O. Ebete, John E. Kountourellis Journal of Chromatography B, 677 (1996) 319-323 30. Rapid and Sensitive Procedure for the Quantitation of Pimethixene in Human Milk and Plasma by Solid Phase Extraction (SPE) Using HPLC K.O. Ebete, J.E. Kountourellis J.Liq. Chrom. & Rel. Technol., 20(5), 789-796 (1997) 31. Isocratic High Performance Liquid Chromatographic Method for the Quantitation of Cyproheptadine in Human Milk and Plasma Using Solvent and Solid Phase Extraction Techniques John E. Kountourellis*, Kenneth O. Ebete, Eleftheria T. Malliou J. Liq. Chrom. & Rel. Technol., 22(4), 603-614 (1999) 32. X-Ray Characterization of 12 Vasolidators in Current Use John E. Kountourellis* and Eleftheria T. Malliou J. Chem. Eng. Data 1999, 44, 656-660 33. High Performance Liquid Chromatographic Determination of Ambroxol in the Presence of Different Preservatives in Pharmaceutical Formulations John E. Koundourellis*, Eleftheria T. Malliou, Theodora A. Broussali Journal of Pharmaceutical and Biomedical Analysis 23(2000) 469-475 34. X-Ray Powder Diffraction Data for 12 Drugs in Current Use John E. Koundourellis* and Eleftheria T. Malliou J. Chem. Eng. Data 2000, 45, 1001-1006 35. Derivative Spectrophotometric and High Performance Liquid Chromato- graphic Determination of Clobutinol in Pharmaceutical Formulations Eleftheria T. Malliou, Constantinos G. Antoniou and John E. Koundourellis Analytical Letters 35(1), 99-109 (2002) 36. FT-IR and Raman Spectroscopic Methods for Identification and Quantitation of Orthorombic and Monoclinic Paracetamol in Powder Mixes Al-Zoubi, J.E. Koundourellis, S. Malamataris Journal of Pharmaceutical and Biomedical Analysis 29(2002) 459-467 37. An Optimized Method for the Simultaneous Determination of Vitamins B1, B6, B12 in Multivitamin Tablets by High Performance Liquid Chromatography C.K. Markopoulou, K.A. Kagkadis, J.E. Koundourellis Journal of Pharmaceutical and Biomedical Analysis 30 (2002) 1403-1410 38. Determination of Butamirate Citrate in Cough Preparations by Derivative UV Spectrophotometry and High Performance Liquid Chromatography Eleftheria T. Malliou, Constantinos G. Antoniou, John E. Koundourellis Analytical Sciences 19 (2003) 563-568 .
Load more

Recommended publications
  • Wo 2010/075090 A2
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date 1 July 2010 (01.07.2010) WO 2010/075090 A2 (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every C07D 409/14 (2006.01) A61K 31/7028 (2006.01) kind of national protection available): AE, AG, AL, AM, C07D 409/12 (2006.01) A61P 11/06 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, (21) International Application Number: DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, PCT/US2009/068073 HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, (22) International Filing Date: KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, 15 December 2009 (15.12.2009) ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, (25) Filing Language: English SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, (26) Publication Language: English TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: (84) Designated States (unless otherwise indicated, for every 61/122,478 15 December 2008 (15.12.2008) US kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, (71) Applicant (for all designated States except US): AUS- ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, PEX PHARMACEUTICALS, INC.
    [Show full text]
  • Transdermal Drug Delivery Device Including An
    (19) TZZ_ZZ¥¥_T (11) EP 1 807 033 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: A61F 13/02 (2006.01) A61L 15/16 (2006.01) 20.07.2016 Bulletin 2016/29 (86) International application number: (21) Application number: 05815555.7 PCT/US2005/035806 (22) Date of filing: 07.10.2005 (87) International publication number: WO 2006/044206 (27.04.2006 Gazette 2006/17) (54) TRANSDERMAL DRUG DELIVERY DEVICE INCLUDING AN OCCLUSIVE BACKING VORRICHTUNG ZUR TRANSDERMALEN VERABREICHUNG VON ARZNEIMITTELN EINSCHLIESSLICH EINER VERSTOPFUNGSSICHERUNG DISPOSITIF D’ADMINISTRATION TRANSDERMIQUE DE MEDICAMENTS AVEC COUCHE SUPPORT OCCLUSIVE (84) Designated Contracting States: • MANTELLE, Juan AT BE BG CH CY CZ DE DK EE ES FI FR GB GR Miami, FL 33186 (US) HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI • NGUYEN, Viet SK TR Miami, FL 33176 (US) (30) Priority: 08.10.2004 US 616861 P (74) Representative: Awapatent AB P.O. Box 5117 (43) Date of publication of application: 200 71 Malmö (SE) 18.07.2007 Bulletin 2007/29 (56) References cited: (73) Proprietor: NOVEN PHARMACEUTICALS, INC. WO-A-02/36103 WO-A-97/23205 Miami, FL 33186 (US) WO-A-2005/046600 WO-A-2006/028863 US-A- 4 994 278 US-A- 4 994 278 (72) Inventors: US-A- 5 246 705 US-A- 5 474 783 • KANIOS, David US-A- 5 474 783 US-A1- 2001 051 180 Miami, FL 33196 (US) US-A1- 2002 128 345 US-A1- 2006 034 905 Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations.
    [Show full text]
  • NVA237 / Glycopyrronium Bromide Multinational, Multi-Database Drug
    Quantitative Safety & Epidemiology NVA237 / Glycopyrronium bromide Non-interventional Final Study Report NVA237A2401T Multinational, multi-database drug utilization study of inhaled NVA237 in Europe Author Document Status Final Date of final version 28 April 2016 of the study report EU PAS register ENCEPP/SDPP/4845 number Property of Novartis Confidential May not be used, divulged, published or otherwise disclosed without the consent of Novartis NIS Report Template Version 2.0 August-13-2014 Novartis Confidential Page 2 Non-interventional study report NVA237A/Seebri® Breezhaler®/CNVA237A2401T PASS information Title Multinational, multi-database drug utilization study of inhaled NVA237 in Europe –Final Study Report Version identifier of the Version 1.0 final study report Date of last version of 28 April 2016 the final study report EU PAS register number ENCEPP/SDPP/4845 Active substance Glycopyrronium bromide (R03BB06) Medicinal product Seebri®Breezhaler® / Tovanor®Breezhaler® / Enurev®Breezhaler® Product reference NVA237 Procedure number SeebriBreezhaler: EMEA/H/C/0002430 TovanorBreezhaler: EMEA/H/C/0002690 EnurevBreezhaler: EMEA/H/C0002691 Marketing authorization Novartis Europharm Ltd holder Frimley Business Park Camberley GU16 7SR United Kingdom Joint PASS No Research question and In the context of the NVA237 marketing authorization objectives application, the Committee for Medicinal Products for Human Use (CHMP) recommended conditions for marketing authorization and product information and suggested to conduct a post-authorization
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2010/0081713 A1 Sharma Et Al
    US 20100081713A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2010/0081713 A1 Sharma et al. (43) Pub. Date: Apr. 1, 2010 (54) COMPOSITIONS AND METHODS FOR (22) Filed: Mar. 18, 2009 TREATINGVIRAL INFECTIONS Related U.S. Application Data (75) Inventors: Geeta Sharma, Singapore (SG); (60) Provisional application No. 61/069,917, filed on Mar. Ralf Altmeyer, Singapore (SG); 19, 2008. Vishal Pendharker, Singapore (SG); Yu Chen, Singapore (SG); Publication Classification Michael Foley, Chestnut Hill, MA (51) Int. Cl. (US) A63L/35 (2006.01) A6II 3L/25 (2006.01) Correspondence Address: A63L/35 (2006.01) Gearhart Law LLC A6II 3/13 (2006.01) 4 Femdale Avenue A6IP3L/2 (2006.01) Chatham, NJ 07928 (US) (52) U.S. Cl. .......... 514/459; 514/529; 514/647: 514/662 (73) Assignee: CombinatoRx, (Singapore) Pte. (57) ABSTRACT Ltd. The present invention provides compositions, methods, and kits for treating or preventing a viral infection (e.g., an infec (21) Appl. No.: 12/406,716 tion caused by an influenza virus). Patent Application Publication Apr. 1, 2010 Sheet 1 of 2 US 2010/0081713 A1 ------ 80 r -0. Vehicle 0.5% HPMC g - - Sertraline-30mg/kg/day - £ 60 “A Sertraline-100mg/kg/day/kg/day i -v. Oseltamivir-30mg/kg/day ...i -0. Oseltamivir-100mg/kg/day -0. (Sertraline 30mg/kg+ . 40 Prednisolone 0.1 mg/Kg) Figure 1 Patent Application Publication Apr. 1, 2010 Sheet 2 of 2 US 2010/0081713 A1 100 468OOO 2 O Wehicle Sentraline 10 mg/kg Sentraline 30mg/kg Setraline 100mg/kg Figure 2 US 2010/008 1713 A1 Apr.
    [Show full text]
  • Marrakesh Agreement Establishing the World Trade Organization
    No. 31874 Multilateral Marrakesh Agreement establishing the World Trade Organ ization (with final act, annexes and protocol). Concluded at Marrakesh on 15 April 1994 Authentic texts: English, French and Spanish. Registered by the Director-General of the World Trade Organization, acting on behalf of the Parties, on 1 June 1995. Multilat ral Accord de Marrakech instituant l©Organisation mondiale du commerce (avec acte final, annexes et protocole). Conclu Marrakech le 15 avril 1994 Textes authentiques : anglais, français et espagnol. Enregistré par le Directeur général de l'Organisation mondiale du com merce, agissant au nom des Parties, le 1er juin 1995. Vol. 1867, 1-31874 4_________United Nations — Treaty Series • Nations Unies — Recueil des Traités 1995 Table of contents Table des matières Indice [Volume 1867] FINAL ACT EMBODYING THE RESULTS OF THE URUGUAY ROUND OF MULTILATERAL TRADE NEGOTIATIONS ACTE FINAL REPRENANT LES RESULTATS DES NEGOCIATIONS COMMERCIALES MULTILATERALES DU CYCLE D©URUGUAY ACTA FINAL EN QUE SE INCORPOR N LOS RESULTADOS DE LA RONDA URUGUAY DE NEGOCIACIONES COMERCIALES MULTILATERALES SIGNATURES - SIGNATURES - FIRMAS MINISTERIAL DECISIONS, DECLARATIONS AND UNDERSTANDING DECISIONS, DECLARATIONS ET MEMORANDUM D©ACCORD MINISTERIELS DECISIONES, DECLARACIONES Y ENTEND MIENTO MINISTERIALES MARRAKESH AGREEMENT ESTABLISHING THE WORLD TRADE ORGANIZATION ACCORD DE MARRAKECH INSTITUANT L©ORGANISATION MONDIALE DU COMMERCE ACUERDO DE MARRAKECH POR EL QUE SE ESTABLECE LA ORGANIZACI N MUND1AL DEL COMERCIO ANNEX 1 ANNEXE 1 ANEXO 1 ANNEX
    [Show full text]
  • Azelastine Hydrochloride
    568 Antihistamines been withdrawn from the market in most countries because of the Preparations treatment of non-allergic rhinitis in adults and children risk of adverse effects. USP 31: Azatadine Maleate Tablets. aged 12 years and over. The dose is 2 sprays into each Astemizole has been given in an oral dose of 10 mg once daily, Proprietary Preparations (details are given in Part 3) nostril twice daily. In the treatment of conjunctivitis, or 5 mg daily in children aged 6 to 12 years. These doses must Austral.: Zadine; Canad.: Optimine; Hong Kong: Zadine†; Malaysia: azelastine is licensed in the UK for the treatment of not be exceeded because of the risk of cardiac arrhythmias with Zadine†; Mex.: Idulamine†; NZ: Zadine†; Singapore: Zadine†; Spain: seasonal allergic conjunctivitis in adults and children higher doses. Lergocil. aged 4 years and over and for the treatment of perenni- The active metabolite of astemizole, tecastemizole (norastemi- Multi-ingredient: Braz.: Cedrin; Canad.: Trinalin; Mex.: Trinalin†; al allergic conjunctivitis in adults and children aged 12 zole) has been investigated for the treatment of allergic rhinitis. Spain: Atiramin; Idulanex; USA: Rynatan†; Trinalin†. years and over. In the USA, it is licensed for the treat- Preparations ment of allergic conjunctivitis in adults and children USP 31: Astemizole Tablets. aged 3 years and over. Regardless of the age and indi- Azelastine Hydrochloride cation, a 0.05% solution is instilled into each eye twice Proprietary Preparations (details are given in Part 3) (BANM, USAN, rINNM) daily; this may be increased to four times daily in se- Arg.: Alermizol†; Astezol†; Cezane†; Mudantil†; Cz.: Hismanal†; Gr.: Mibiron†; Tulipe-R†; Tyrenol†; Waruzol†; India: Astizole; Stemiz†; Mex.: A-5610 (azelastine or azelastine hydrochloride); Atselastiinihy- vere conditions.
    [Show full text]
  • BMJ Open Is Committed to Open Peer Review. As Part of This Commitment We Make the Peer Review History of Every Article We Publish Publicly Available
    BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available. When an article is published we post the peer reviewers’ comments and the authors’ responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to. The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript. BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (http://bmjopen.bmj.com). If you have any questions on BMJ Open’s open peer review process please email [email protected] BMJ Open Pediatric drug utilization in the Western Pacific region: Australia, Japan, South Korea, Hong Kong and Taiwan Journal: BMJ Open ManuscriptFor ID peerbmjopen-2019-032426 review only Article Type: Research Date Submitted by the 27-Jun-2019 Author: Complete List of Authors: Brauer, Ruth; University College London, Research Department of Practice and Policy, School of Pharmacy Wong, Ian; University College London, Research Department of Practice and Policy, School of Pharmacy; University of Hong Kong, Centre for Safe Medication Practice and Research, Department
    [Show full text]
  • Vr Meds Ex01 3B 0825S Coding Manual Supplement Page 1
    vr_meds_ex01_3b_0825s Coding Manual Supplement MEDNAME OTHER_CODE ATC_CODE SYSTEM THER_GP PHRM_GP CHEM_GP SODIUM FLUORIDE A12CD01 A01AA01 A A01 A01A A01AA SODIUM MONOFLUOROPHOSPHATE A12CD02 A01AA02 A A01 A01A A01AA HYDROGEN PEROXIDE D08AX01 A01AB02 A A01 A01A A01AB HYDROGEN PEROXIDE S02AA06 A01AB02 A A01 A01A A01AB CHLORHEXIDINE B05CA02 A01AB03 A A01 A01A A01AB CHLORHEXIDINE D08AC02 A01AB03 A A01 A01A A01AB CHLORHEXIDINE D09AA12 A01AB03 A A01 A01A A01AB CHLORHEXIDINE R02AA05 A01AB03 A A01 A01A A01AB CHLORHEXIDINE S01AX09 A01AB03 A A01 A01A A01AB CHLORHEXIDINE S02AA09 A01AB03 A A01 A01A A01AB CHLORHEXIDINE S03AA04 A01AB03 A A01 A01A A01AB AMPHOTERICIN B A07AA07 A01AB04 A A01 A01A A01AB AMPHOTERICIN B G01AA03 A01AB04 A A01 A01A A01AB AMPHOTERICIN B J02AA01 A01AB04 A A01 A01A A01AB POLYNOXYLIN D01AE05 A01AB05 A A01 A01A A01AB OXYQUINOLINE D08AH03 A01AB07 A A01 A01A A01AB OXYQUINOLINE G01AC30 A01AB07 A A01 A01A A01AB OXYQUINOLINE R02AA14 A01AB07 A A01 A01A A01AB NEOMYCIN A07AA01 A01AB08 A A01 A01A A01AB NEOMYCIN B05CA09 A01AB08 A A01 A01A A01AB NEOMYCIN D06AX04 A01AB08 A A01 A01A A01AB NEOMYCIN J01GB05 A01AB08 A A01 A01A A01AB NEOMYCIN R02AB01 A01AB08 A A01 A01A A01AB NEOMYCIN S01AA03 A01AB08 A A01 A01A A01AB NEOMYCIN S02AA07 A01AB08 A A01 A01A A01AB NEOMYCIN S03AA01 A01AB08 A A01 A01A A01AB MICONAZOLE A07AC01 A01AB09 A A01 A01A A01AB MICONAZOLE D01AC02 A01AB09 A A01 A01A A01AB MICONAZOLE G01AF04 A01AB09 A A01 A01A A01AB MICONAZOLE J02AB01 A01AB09 A A01 A01A A01AB MICONAZOLE S02AA13 A01AB09 A A01 A01A A01AB NATAMYCIN A07AA03 A01AB10 A A01
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • 2 12/ 35 74Al
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date 22 March 2012 (22.03.2012) 2 12/ 35 74 Al (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 9/16 (2006.01) A61K 9/51 (2006.01) kind of national protection available): AE, AG, AL, AM, A61K 9/14 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, (21) International Application Number: DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, PCT/EP201 1/065959 HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, (22) International Filing Date: KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, 14 September 201 1 (14.09.201 1) ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, (25) Filing Language: English RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, (26) Publication Language: English TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: 61/382,653 14 September 2010 (14.09.2010) US (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, (71) Applicant (for all designated States except US): GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, NANOLOGICA AB [SE/SE]; P.O Box 8182, S-104 20 ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, Stockholm (SE).
    [Show full text]
  • Wo 2008/127291 A2
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date PCT (10) International Publication Number 23 October 2008 (23.10.2008) WO 2008/127291 A2 (51) International Patent Classification: Jeffrey, J. [US/US]; 106 Glenview Drive, Los Alamos, GOlN 33/53 (2006.01) GOlN 33/68 (2006.01) NM 87544 (US). HARRIS, Michael, N. [US/US]; 295 GOlN 21/76 (2006.01) GOlN 23/223 (2006.01) Kilby Avenue, Los Alamos, NM 87544 (US). BURRELL, Anthony, K. [NZ/US]; 2431 Canyon Glen, Los Alamos, (21) International Application Number: NM 87544 (US). PCT/US2007/021888 (74) Agents: COTTRELL, Bruce, H. et al.; Los Alamos (22) International Filing Date: 10 October 2007 (10.10.2007) National Laboratory, LGTP, MS A187, Los Alamos, NM 87545 (US). (25) Filing Language: English (81) Designated States (unless otherwise indicated, for every (26) Publication Language: English kind of national protection available): AE, AG, AL, AM, AT,AU, AZ, BA, BB, BG, BH, BR, BW, BY,BZ, CA, CH, (30) Priority Data: CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, 60/850,594 10 October 2006 (10.10.2006) US ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, (71) Applicants (for all designated States except US): LOS LR, LS, LT, LU, LY,MA, MD, ME, MG, MK, MN, MW, ALAMOS NATIONAL SECURITY,LLC [US/US]; Los MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, Alamos National Laboratory, Lc/ip, Ms A187, Los Alamos, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, NM 87545 (US).
    [Show full text]
  • European Patent Office
    Europäisches Patentamt *EP001021204B1* (19) European Patent Office Office européen des brevets (11) EP 1 021 204 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.7: A61K 47/32, A61L 25/00 of the grant of the patent: 28.12.2005 Bulletin 2005/52 (86) International application number: PCT/US1998/020091 (21) Application number: 98949505.6 (87) International publication number: (22) Date of filing: 25.09.1998 WO 1999/015210 (01.04.1999 Gazette 1999/13) (54) BIOADHESIVE COMPOSITIONS AND METHODS FOR TOPICAL ADMINISTRATION OF ACTIVE AGENTS BIOLOGISCHE KLEBER UND VERFAHREN ZUR TOPISCHEN VERABREICHUNG VON WIRKSTOFFEN COMPOSITIONS BIOADHESIVES ET METHODES D’ADMINISTRATION LOCALE D’AGENTS ACTIFS (84) Designated Contracting States: • HOUZE, David AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU Miami, FL 33186 (US) MC NL PT SE • KANIOS, David Miami, FL 33196 (US) (30) Priority: 26.09.1997 US 61155 P (74) Representative: Isenbruck, Günter (43) Date of publication of application: Isenbruck, Bösl, Hörschler, Wichmann, Huhn 26.07.2000 Bulletin 2000/30 Patentanwälte Theodor-Heuss-Anlage 12 (73) Proprietor: NOVEN PHARMACEUTICALS, INC. 68165 Mannheim (DE) Miami, FL 33186 (US) (56) References cited: (72) Inventors: FR-A- 2 532 546 GB-A- 1 050 070 • MANTELLE, Juan GB-A- 2 046 773 US-A- 4 593 053 Miami, FL 33176 (US) US-A- 5 656 286 Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted.
    [Show full text]